Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

BrUOG 413: A Phase II Study of Adjuvant Trastuzumab Deruxtecan (Enhertu) + Nivolumab For Patients Who Are Disease Free After Completion of Trimodality Treatment For HER-2-Positive Cancers of the Esophagus and Gastroesophageal Junction

NCT05480384 is registered in ClinicalTrials.gov with Brown University as lead sponsor.

NCT NCT05480384
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05480384 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
BrUOG 413: A Phase II Study of Adjuvant Trastuzumab Deruxtecan (Enhertu) + Nivolumab For Patients Who Are Disease Free After Completion of Trimodality Treatment For HER-2-Positive Cancers of the Esophagus and Gastroesophageal Junction
Lead sponsor
Brown University
Phase
Phase 2
Overall status
Active, not recruiting
Start date
July 14, 2023
Completion date
May 31, 2026
Enrollment
1 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

esophageal adenocarcinoma, esophageal cancer, gastroesophageal-junction cancer, her-2 protein overexpression